Innovent Biologics of Suzhou and Hutchison China MediTech (Chi-Med) expanded their global collaboration to include a combination of Innovent’s approved PD-1 drug, Tyvyt®, and Chi-Med’s surufatinib. The China-US tests will enroll patients with solid tumors. Surufatinib is a novel inhibitor of vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor 1 (FGFR1) and colony stimulating factor-1 receptor (CSF-1R). Previously, Innovent and Chi-Med agreed to test a combination of Tyvyt and Chi-Med’s approved VEGFR inhibitor, fruquintinib.
Source: China Biotoday
